Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes (UPGRADE)
A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Aspart (NovoRapid® ) or Soluble Human Insulin for the Treatment of Diabetes Mellitus the UPGRADE Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Rome, Italy, 00144
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with type 2 diabetes
- Treatment with Insulin Aspart (NovoRapid®) or Soluble Human Insulin for minimum 3 months and maximum 3 years
Exclusion Criteria:
- Patients with an end-stage renal failure
- Patients with a serious liver disease
- Patients with concomitant malignant disease
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
A
|
Observational study; use of the products as in the normal clinical practice conditions
Other Names:
|
|
B
|
Observational study; use of the products as in the normal clinical practice conditions
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of major hypoglycaemic events reported as serious adverse drug reactions
Time Frame: after 26 weeks
|
after 26 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of serious and non serious drug reactions
Time Frame: during 26 weeks
|
during 26 weeks
|
|
Number of serious adverse event
Time Frame: during 26 weeks
|
during 26 weeks
|
|
Number of all major (daytime and nocturnal) hypoglycaemic events
Time Frame: during 26 weeks
|
during 26 weeks
|
|
Number of major hypoglycaemic events related to omission of a meal after injection
Time Frame: during 26 weeks
|
during 26 weeks
|
|
Number of major hypoglycaemic events related to physical exercise of at least 30 min duration
Time Frame: during 26 weeks
|
during 26 weeks
|
|
Number of all minor (daytime and nocturnal) hypoglycaemic events during 4 weeks preceding each study visit
Time Frame: after 26 weeks
|
after 26 weeks
|
|
Weight and waist circumference change
Time Frame: during 26 weeks
|
during 26 weeks
|
|
Number of hypoglycaemia events in the two different treatment groups based on the HbA1c level
Time Frame: after 26 weeks
|
after 26 weeks
|
|
Quality of Life (QoL)
Time Frame: after 26 weeks
|
after 26 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ANA-1897
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.